Ray A. Ohara

Ray A. Ohara

Auto-generated profile, based on publicly available information

Ray A. Ohara

Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GEGospel Enyindah-Asonye
Gospel Enyindah-Asonye
YLYan Li
Yan Li
JRJeffrey H. Ruth
Jeffrey H. Ruth
DSDanislav Spassov
Danislav Spassov
KHKatie E. Hebron
Katie E. Hebron
FLFeng Lin
Feng Lin
Significance: The CD6 T cell surface glycoprotein regulates T cell activation, andCD6is a risk gene for autoimmune diseases including multiple sclerosis (MS). Moreover, recent work indicates that CD6 is an attractive target for the development of new therapeutic approaches to autoimmune diseases such as MS. The known ligand of CD6 is CD166 (also termed ALCAM), but CD6–CD166 interactions neither explain CD6-dependent interactions with stromal cell lineages that are critical in organ-targeted autoimmune diseases nor account for effects of CD6-targeted therapeutics in autoimmune diseases. This report definitively establishes CD318 as a second ligand of CD6 and provides evidence for the importance of CD6–CD318 interactions in autoimmune diseases that affect the central nervous system and the synovial lining of joints.

21 October 2022 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
RWRenee Wu
Renee Wu
RORay A. Ohara
Ray A. Ohara
SJSuin Jo
Suin Jo
TLTian-Tian Liu
Tian-Tian Liu
SFStephen T. Ferris
Stephen T. Ferris
KMKenneth M. Murphy
Kenneth M. Murphy

13 August 2020 in Immunity
Verified
Journal Article
Closed access
SKSunkyung Kim
Sunkyung Kim
PBPrachi Bagadia
Prachi Bagadia
DADavid A. Anderson
David A. Anderson
TLTian-Tian Liu
Tian-Tian Liu
XHXiao Huang
Xiao Huang
KMKenneth M. Murphy
Kenneth M. Murphy

1 June 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
SFStephen T. Ferris
Stephen T. Ferris
RORay A. Ohara
Ray A. Ohara
FOFeiya Ou
Feiya Ou
RWRenee Wu
Renee Wu
XHXiao Huang
Xiao Huang
KMKenneth M. Murphy
Kenneth M. Murphy
As a cell-based cancer vaccine, dendritic cells (DC), derived from peripheral blood monocytes or bone marrow (BM) treated with GM-CSF (GMDC), were initially thought to induce antitumor immunity by presenting tumor antigens directly to host T cells. Subsequent work revealed that GMDCs do not directly prime tumor-specific T cells, but must transfer their antigens to host DCs. This reduces their advantage over strictly antigen-based strategies proposed as cancer vaccines. Type 1 conventional DCs (cDC1) have been reported to be superior to GMDCs as a cancer vaccine, but whether they act by transferring antigens to host DCs is unknown. To test this, we compared antitumor responses induced by GMDCs and cDC1 in Irf8 +32–/– mice, which lack endogenous cDC1 and cannot reject immunogenic fibrosarcomas. Both GMDCs and cDC1 could cross-present cell-associated antigens to CD8+ T cells in vitro. However, injection of GMDCs into tumors in Irf8 +32–/– mice did not induce antitumor immunity, consistent with their reported dependence on host cDC1. In contrast, injection of cDC1s into tumors in Irf8 +32–/– mice resulted in their migration to tumor-draining lymph nodes, activation of tumor-specific CD8+ T cells, and rejection of the tumors. Tumor rejection did not require the in vitro loading of cDC1 with antigens, indicating that acquisition of antigens in vivo is sufficient to induce antitumor responses. Finally, cDC1 vaccination showed abscopal effects, with rejection of untreated tumors growing concurrently on the opposite flank. These results suggest that cDC1 may be a useful future avenue to explore for antitumor therapy. See related Spotlight by Hubert et al., p. 918

12 February 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
MOMartin J. O’bRien
Martin J. O’bRien
QSQiang Shu
Qiang Shu
WSW.ALexander Stinson
W.ALexander Stinson
PTPei-Suen Tsou
Pei-Suen Tsou
JRJeffrey H. Ruth
Jeffrey H. Ruth
MAM. Asif Amin
M. Asif Amin
Galectin-9 (Gal-9) is a mammalian lectin secreted by endothelial cells that is highly expressed in rheumatoid arthritis synovial tissues and synovial fluid. Roles have been proposed for galectins in the regulation of inflammation and angiogenesis. Therefore, we examined the contribution of Gal-9 to angiogenesis and inflammation in arthritis. To determine the role of Gal-9 in angiogenesis, we performed human dermal microvascular endothelial cell (HMVEC) chemotaxis, Matrigel tube formation, and mouse Matrigel plug angiogenesis assays. We also examined the role of signaling molecules in Gal-9-induced angiogenesis by using signaling inhibitors and small interfering RNA (siRNA). We performed monocyte (MN) migration assays in a modified Boyden chamber and assessed the arthritogenicity of Gal-9 by injecting Gal-9 into mouse knees. Gal-9 significantly increased HMVEC migration, which was decreased by inhibitors of extracellular signal-regulating kinases 1/2 (Erk1/2), p38, Janus kinase (Jnk), and phosphatidylinositol 3-kinase. Gal-9 HMVEC-induced tube formation was reduced by Erk1/2, p38, and Jnk inhibitors, and this was confirmed by siRNA knockdown. In mouse Matrigel plug assays, plugs containing Gal-9 induced significantly higher angiogenesis, which was attenuated by a Jnk inhibitor. Gal-9 also induced MN migration, and there was a marked increase in MN ingress when C57BL/6 mouse knees were injected with Gal-9 compared with the control, pointing to a proinflammatory role for Gal-9. Gal-9 mediates angiogenesis, increases MN migration in vitro, and induces acute inflammatory arthritis in mice, suggesting a novel role for Gal-9 in angiogenesis, joint inflammation, and possibly other inflammatory diseases.

11 July 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SKSunkyung Kim
Sunkyung Kim
JCJing Chen
Jing Chen
SJSuin Jo
Suin Jo
FOFeiya Ou
Feiya Ou
SFStephen T. Ferris
Stephen T. Ferris
KMKenneth M. Murphy
Kenneth M. Murphy
Cytokines produced in association with tumors can impair antitumor immune responses by reducing the abundance of type 1 conventional dendritic cells (cDC1), but the mechanism remains unclear. Here, we show that tumor-derived IL-6 generally reduces cDC development but selectively impairs cDC1 development in both murine and human systems through the induction of C/EBPβ in the common dendritic cell progenitor (CDP). C/EBPβ and NFIL3 compete for binding to sites in the Zeb2 −165 kb enhancer and support or repress Zeb2 expression, respectively. At homeostasis, pre-cDC1 specification occurs upon Nfil3 induction and consequent Zeb2 suppression. However, IL-6 strongly induces C/EBPβ expression in CDPs. Importantly, the ability of IL-6 to impair cDC development is dependent on the presence of C/EBPβ binding sites in the Zeb2 −165 kb enhancer, as this effect is lost in Δ1+2+3 mutant mice in which these binding sites are mutated. These results explain how tumor-associated IL-6 suppresses cDC1 development and suggest therapeutic approaches preventing abnormal C/EBPβ induction in CDPs may help reestablish cDC1 development to enhance antitumor immunity.